BioCentury | Nov 17, 2017
Clinical News

BerGenBio starts Phase II of BGB324 to treat TNBC

...treated, locally advanced or metastatic triple-negative breast cancer (TNBC) or triple negative inflammatory breast cancer (TN-IBC...
BioCentury | Jul 15, 2013
Company News

XL-protein, IBC Generium deal

XL-protein granted Generium exclusive development and commercialization rights to an undisclosed PASylated blood clotting factor in Russia and the Commonwealth of Independent States. XL-protein will also apply its PASylation technology for plasma-half life extension to...
BioCentury | Jun 3, 2013
Company News

Alethia, International Biotech Center (IBC) Generium deal

...Alethia and IBC Generium partnered to co-develop Alethia's AB-16B5 , an IgG2 mAb against clusterin (CLU...
...IBC will share profits in territories outside Russia and the Commonwealth of Independent States (CIS). IBC...
...did not disclose further financial terms. Alethia BioTherapeutics Inc. , Montreal, Quebec International Biotech Center (IBC...
BioCentury | Jul 9, 2012
Company News

Affitech, IBC Generium deal

...Affitech's Affitech Research A/S subsidiary and IBC Generium signed a binding term sheet to grant IBC...
...will be eligible for payment upon successful transfer of the technology, plus annual license fees. IBC...
...also be eligible for milestones and royalties on the products developed by IBC using MBAS. IBC...
BioCentury | Apr 23, 2012
Clinical News

r84: Phase I start

...Center Generium (IBC Generium) will begin a Russian Phase I trial of AT001. Last year, IBC...
BioCentury | Dec 5, 2011
Company News

Affitech, IBC Generium deal

...to develop and commercialize Affitech's cancer candidate AT008 . Affitech received €2 million ($2.7 million). IBC...
...NauchTekhStroy Plus LLC ( NTS Plus) transferred rights to develop and commercialize the compounds to IBC...
...preclinical testing (see BioCentury, June, 27). Affitech A/S (CSE:AFFI), Copenhagen, Denmark International Biotech Center Generium (IBC...
BioCentury | Oct 24, 2011
Company News

Affitech deal

...Affitech received a €2.5 million ($3.5 million) milestone payment from International Biotech Center Generium (IBC Generium...
...mAb against VEGF receptor 2 ( KDR/Flk-1 ; VEGFR-2 ) in preclinical testing for cancer. IBC...
BioCentury | Jun 27, 2011
Company News

Affitech, Pharmstandard deal

...of the Commonwealth of Independent States to newco International Biotech Center Generium (IBC Generium) . IBC...
...the park's development portfolio. Affitech said that Shuster and Pharmstandard's Victor Kharitonin decided to establish IBC...
BioCentury | Oct 5, 2009
Clinical News

Amunix, Versartis preclinical data

...dose to maintain glycemic control in Type II diabetic patients. Data were presented at the IBC...
BioCentury | Oct 5, 2009
Clinical News

Amunix, Versartis preclinical data

...pharmacodynamic studies from monkeys support monthly VRS-317 to treat GHD. Data were presented at the IBC...
Items per page:
1 - 10 of 32
BioCentury | Nov 17, 2017
Clinical News

BerGenBio starts Phase II of BGB324 to treat TNBC

...treated, locally advanced or metastatic triple-negative breast cancer (TNBC) or triple negative inflammatory breast cancer (TN-IBC...
BioCentury | Jul 15, 2013
Company News

XL-protein, IBC Generium deal

XL-protein granted Generium exclusive development and commercialization rights to an undisclosed PASylated blood clotting factor in Russia and the Commonwealth of Independent States. XL-protein will also apply its PASylation technology for plasma-half life extension to...
BioCentury | Jun 3, 2013
Company News

Alethia, International Biotech Center (IBC) Generium deal

...Alethia and IBC Generium partnered to co-develop Alethia's AB-16B5 , an IgG2 mAb against clusterin (CLU...
...IBC will share profits in territories outside Russia and the Commonwealth of Independent States (CIS). IBC...
...did not disclose further financial terms. Alethia BioTherapeutics Inc. , Montreal, Quebec International Biotech Center (IBC...
BioCentury | Jul 9, 2012
Company News

Affitech, IBC Generium deal

...Affitech's Affitech Research A/S subsidiary and IBC Generium signed a binding term sheet to grant IBC...
...will be eligible for payment upon successful transfer of the technology, plus annual license fees. IBC...
...also be eligible for milestones and royalties on the products developed by IBC using MBAS. IBC...
BioCentury | Apr 23, 2012
Clinical News

r84: Phase I start

...Center Generium (IBC Generium) will begin a Russian Phase I trial of AT001. Last year, IBC...
BioCentury | Dec 5, 2011
Company News

Affitech, IBC Generium deal

...to develop and commercialize Affitech's cancer candidate AT008 . Affitech received €2 million ($2.7 million). IBC...
...NauchTekhStroy Plus LLC ( NTS Plus) transferred rights to develop and commercialize the compounds to IBC...
...preclinical testing (see BioCentury, June, 27). Affitech A/S (CSE:AFFI), Copenhagen, Denmark International Biotech Center Generium (IBC...
BioCentury | Oct 24, 2011
Company News

Affitech deal

...Affitech received a €2.5 million ($3.5 million) milestone payment from International Biotech Center Generium (IBC Generium...
...mAb against VEGF receptor 2 ( KDR/Flk-1 ; VEGFR-2 ) in preclinical testing for cancer. IBC...
BioCentury | Jun 27, 2011
Company News

Affitech, Pharmstandard deal

...of the Commonwealth of Independent States to newco International Biotech Center Generium (IBC Generium) . IBC...
...the park's development portfolio. Affitech said that Shuster and Pharmstandard's Victor Kharitonin decided to establish IBC...
BioCentury | Oct 5, 2009
Clinical News

Amunix, Versartis preclinical data

...dose to maintain glycemic control in Type II diabetic patients. Data were presented at the IBC...
BioCentury | Oct 5, 2009
Clinical News

Amunix, Versartis preclinical data

...pharmacodynamic studies from monkeys support monthly VRS-317 to treat GHD. Data were presented at the IBC...
Items per page:
1 - 10 of 32